Tevis Investment Management Purchases 358 Shares of Johnson & Johnson (NYSE:JNJ)

Tevis Investment Management lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 17,692 shares of the company’s stock after acquiring an additional 358 shares during the quarter. Johnson & Johnson comprises approximately 1.9% of Tevis Investment Management’s portfolio, making the stock its 16th largest holding. Tevis Investment Management’s holdings in Johnson & Johnson were worth $2,559,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Legacy Financial Strategies LLC boosted its stake in shares of Johnson & Johnson by 6.4% in the 4th quarter. Legacy Financial Strategies LLC now owns 4,073 shares of the company’s stock worth $587,000 after buying an additional 245 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Johnson & Johnson in the fourth quarter worth about $518,000. Kestra Private Wealth Services LLC grew its stake in shares of Johnson & Johnson by 5.9% during the 4th quarter. Kestra Private Wealth Services LLC now owns 110,408 shares of the company’s stock valued at $15,967,000 after purchasing an additional 6,187 shares during the period. Stephens Inc. AR increased its position in shares of Johnson & Johnson by 0.4% during the 4th quarter. Stephens Inc. AR now owns 202,348 shares of the company’s stock valued at $29,264,000 after purchasing an additional 793 shares during the last quarter. Finally, Rede Wealth LLC lifted its stake in shares of Johnson & Johnson by 0.5% in the 4th quarter. Rede Wealth LLC now owns 38,258 shares of the company’s stock worth $5,533,000 after purchasing an additional 173 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ? increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Barclays boosted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Raymond James lowered their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Trading Down 0.6 %

JNJ stock opened at $155.23 on Thursday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm’s fifty day simple moving average is $147.48 and its two-hundred day simple moving average is $156.01. The stock has a market capitalization of $373.73 billion, a price-to-earnings ratio of 23.34, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.29 earnings per share. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.20%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.